Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019045774) ALLOGENEIC CAR-T PLATFORM USING HLA-MATCHED BANK OF IPSCS, AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/045774 International Application No.: PCT/US2018/022319
Publication Date: 07.03.2019 International Filing Date: 14.03.2018
IPC:
A61K 35/17 (2015.01) ,C07K 14/705 (2006.01) ,C07K 16/30 (2006.01) ,C07K 14/725 (2006.01) ,C12N 5/0783 (2010.01)
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
725
T-cell receptors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
Applicants:
ORIG3N, INC. [US/US]; 27 Drydock Ave., 6th Floor Boston, Massachusetts 02210, US
Inventors:
SMITH, Robin Y.; US
GLICKSMAN, Marcie A.; US
Agent:
HAULBROOK, William R.; US
ADATO, Ronen; US
AUGST, Alexander D.; US
BYCHOWSKI, Meaghan E.; US
BUTEAU, Kristen C.; US
CAHILL, John J.; US
JARRELL, Brenda Herschbach; US
KLEIN, Daniel A.; US
LI, Xiaodong; US
LUCA, Cassandra G.; US
LYON, Charles E.; US
MEDINA, Rolando; US
MONROE, Margo R.; US
NGUYEN, Suzanne P.; US
PACE, Nicholas J.; US
PYSHER, Paul A.; US
REARICK, John P.; US
REESE, Brian E.; US
ROHLFS, Elizabeth M.; US
SAHR, Robert N.; US
SCHONEWALD, Stephanie L.; US
SHAIKH, Nishat A.; US
SHINALL, Michael A.; US
SHORE, David E.; US
SMITH, Maria C.; US
SUH, Su Kyung; US
VETTER, Michael L.; US
VRABLIK, Tracy L.; US
Priority Data:
62/553,55001.09.2017US
Title (EN) ALLOGENEIC CAR-T PLATFORM USING HLA-MATCHED BANK OF IPSCS, AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS
(FR) PLATE-FORME CAR-T ALLOGÉNIQUE UTILISANT UNE BANQUE DE CELLULES SOUCHES PLURIPOTENTES INDUITES CORRESPONDANT AU SYSTÈME HLA, ET COMPOSITIONS, SYSTÈMES ET PROCÉDÉS ASSOCIÉS
Abstract:
(EN) Presented herein are systems and methods of producing "universal" and/or "off-the-shelf" CAR-T compositions suitable for cancer therapy to be administered to one or more individuals. A CAR-T composition is a composition comprising one or more types of chimeric antigen receptor T cells (CAR-T). The iPSCs and/or cell lines, and any iPSC-derived CAR-T compositions derived therefrom, are identified as compatible with one or more individuals using an identification of a cell type indicative of compatibility (e.g., HLA match and/or ABO blood match and/or RHD blood match). The compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a donor. The retrieved compatible cells are then used to derive iPSC-derived CAR-T compositions, wherein the derived compositions are suitable for therapy of one or more individuals.
(FR) L'invention concerne des systèmes et des procédés de production de compositions de CAR-T « universelles » et/ou « standard » appropriées pour une thérapie anticancéreuse à administrer à un ou plusieurs individus. Une composition de CAR-T est une composition comprenant un ou plusieurs types de lymphocytes T à récepteurs antigéniques chimériques (CAR-T). Les cellules souches pluripotentes induites (iPSC) et/ou les lignées cellulaires, et des compositions de CAR-T dérivés d'iPSC quelconques dérivées de celles-ci, sont identifiées comme étant compatibles avec un ou plusieurs individus à l'aide d'une identification d'un type de cellule indiquant une compatibilité (par exemple, une correspondance au système HLA et/ou une correspondance au système ABO et/ou une correspondance au système Rhésus). Les cellules compatibles sont ensuite récupérées d'un référentiel géré à indexation HLA (et/ou indexé autrement) ou sont dérivées d'un échantillon biologique d'un donneur. Les cellules compatibles récupérées sont ensuite utilisées pour dériver des compositions de CAR-T dérivés d'iPSC, les compositions dérivées étant appropriées pour une thérapie d'un ou plusieurs individus.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)